Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ociperlimab + tislelizumab versus pembrolizumab in previously untreated PD-L1-selected advanced non-small cell lung cancer
2020-004985-21Phase 3Active
- Sponsor
- BeiGene
- Start
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Ociperlimab + tislelizumab with Keytruda + placebo (2 arms). Primary endpoint: Progression-free survival assessed by investigators. Started Apr 2021; status: active.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-004985-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004985-21.